Nutritional research is important for advancing our understanding of foods and nutrients and their critical impact on human health. By examining the complex interactions between nutrients, our bodies, and disease, these studies reveal powerful strategies for the prevention and management of a variety of health conditions.
The finalists for this year’s award demonstrate the transformative power of such research, tackling important challenges and uncovering new solutions in the field of nutrition.
Announcement of winners
The award will be presented at a VIP party hosted by NutraIngredients on May 15 in Geneva, Switzerland, to recognize forward-thinking initiatives and products across industry categories and celebrate the award’s 10th anniversary.
Nicky Hancox, editor of NutraIngredients.com, said: “We have a fantastic field of players in this year’s finals and the team is excited to celebrate a huge milestone for the brand as well as celebrate the deserving finalists and winners. “I’m working on it,” he said.
Probiotic strain LpHEAL9 as a potential psychobiotic
In response to the prevalence of mental health conditions and the need for natural, sustainable interventions, Probi joins the significantly growing body of evidence highlighting the potential for probiotics to impact the mind through the gut-brain axis. We tried to build on that.
Provi’s research project included the completion of multiple randomized controlled human trials investigating its research. Lactiplantibacillus plantarumHEAL9 (LpHEAL9) probiotic strain and its effects on cognition, mood, and sleep.
Healthy participants received 10 billion CFU of LpHEAL9 or a placebo daily for 4 to 12 weeks. The first study involved 129 adults and found that taking probiotics significantly reduced stress and cortisol arousal, as well as cognitive test scores. The results show potential for improving sleep and mood. A further study in 107 adults identified LpHEAL9 to be associated with significant reductions in inflammatory markers and cortisol levels.
Overall, Probi’s research demonstrates that its LpHEAL9 strain has significant potential as a psychobiological agent, with results suggesting benefits for cognition, sleep, and mood.
Citicoline and docosahecenoic acid for glaucoma patients
Glaucoma is the second leading cause of vision loss. With glaucoma expected to affect more than 111 million people between the ages of 40 and 80 by 2040, the Brudy Institute has established a limited research program to investigate the potential of natural nutrition-based interventions for the treatment of glaucoma. We sought to build on evidence.
Specifically, the company investigated the effects of citicoline and docosahecenoic acid (DHA) on visual field in glaucoma patients in a randomized controlled trial. The study involved 73 participants, each assigned to one of four groups: Group 1 (vitamin C), Group 2 (DHA), Group 3 (citicoline), and Group 4 (DHA + citicoline). Ta.
Mean deficits were found to be significantly improved only in patients who took DHA in combination with citicoline, suggesting a synergistic effect of the two compounds on ganglion cell function. Furthermore, the slope of the visual field index improved significantly within this group.
Uncovering the potential of NAD+ for healthy aging
ChromadDex’s External Research Program (CERP) is a program that accelerates bioscience advances through research into the company’s patented nicotinamide riboside (NR) component, nicotinamide adenine dinucleotide (NAD+) in the field of healthy aging. reflects the current strong interest in the science of studying .
The company’s human randomized controlled trial involved 20 participants with Parkinson’s disease (PD) who received either NR 1500 mg twice daily or a placebo for four weeks. The NR intervention was found to be associated with clinical improvement in scores assessing the clinical severity of PD measured using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
The researchers emphasized that this result supports future studies increasing the NR dose to 3000 mg per day in phase II clinical trials.
